Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Muscular Atrophy, Spinal: full-pipeline trial registry
6 of 16 indexed Muscular Atrophy, Spinal trials are currently recruiting.
Corpus placement: #1,060 of 28,707 conditions by registered trial count.
16 US clinical trials · 6 currently recruiting · #1,060 of 28,707 conditions by registered trial count
Muscular Atrophy, Spinal: 16 US clinical trials tracked, 6 recruiting.
Muscular Atrophy, Spinal is the subject of 16 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Hoffmann-La Roche, running 7 of these trials.
Enrollment posture brief
Registry condition muscular-atrophy-spinal
OPEN 6 | RECR 38% | LATE 6 | EARLY 7 | RANK #1060 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Acute-graft-versus-host Disease (38% recruiting · 8 trials)
Muscular Atrophy, Spinal lists 6 open slots (38% of 16 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Muscular Atrophy, Spinal on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Muscular Atrophy, Spinal is recruiting below its size-band peers.
6 of 16 indexed trials (37.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Muscular Atrophy, Spinal research.
Hoffmann-La Roche accounts for 7 of 16 trials (43.8%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Muscular Atrophy, Spinal trials plan to enrol fewer than 100 people.
Median target enrolment is 30 among the 16 trials that report a genuine target (sentinel values excluded). 12 of those (75%) plan for fewer than 100 participants.
-
Muscular Atrophy, Spinal research is mostly interventional.
14 interventional and 2 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
16 total, page 1 of 1
A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)
Biogen
NCT06555419
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
Biogen
NCT07221669
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy
Hoffmann-La Roche
NCT05861999
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
Hoffmann-La Roche
NCT05861986
A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA) Who Took it Before or During Pregnancy And About The Health of Their Babies
Biogen
NCT05789758
A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy
Hoffmann-La Roche
NCT05808764
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
Scholar Rock
NCT05626855
A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)
Biogen
NCT04729907
A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
Hoffmann-La Roche
NCT03779334
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants
Hoffmann-La Roche
NCT02908685
Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam
Scholar Rock
NCT05156320
An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy
Scholar Rock
NCT03921528
A Study to Collect Blood Samples From Patients With Spinal Muscular Atrophy for Biomarker Analysis
Hoffmann-La Roche
NCT01910168
A Pilot Therapeutic Trial Using Hydroxyurea in Type I Spinal Muscular Atrophy Patients
Stanford University
NCT00568698
A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety and Tolerability of a Single Oral Dose of Risdiplam Compared to Matched Healthy Participants With Normal Hepatic Function
Hoffmann-La Roche
NCT03920865
Progressive Strength Training in Spinal Muscular Atrophy
University of Utah
NCT01233817
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 4 |
| Phase 3 | 4 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Muscular Atrophy, Spinal records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Muscular Atrophy, Spinal trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Muscular Atrophy, Spinal page
16 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Muscular Atrophy, Spinal trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Hoffmann-La Roche sponsors the most Muscular Atrophy, Spinal trials on record, review their full trial history before evaluating a specific study. See Hoffmann-La Roche's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Muscular Atrophy, Spinal condition card totals 16 registered trials; most-linked intervention Risdiplam; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.